Results 111 to 120 of about 69,136 (185)

I "Gut" Rhythm: the microbiota as a modulator of the stress response and circadian rhythms

The FEBS Journal, Volume 292, Issue 6, Page 1454-1479, March 2025.
The stress response and circadian rhythms are essential to maintain appropriate responses to the environment and are known to be impacted by the gut microbiota. Due to the interconnected nature of these important components of physiology, in this review we explore how the gut microbiota may play a role in regulating the integration of stress and ...
Gabriel S. S. Tofani, Gerard Clarke, John F. Cryan   +2 more
wiley   +1 more source

Succinate receptor 1 signaling mutually depends on subcellular localization and cellular metabolism

The FEBS Journal, Volume 292, Issue 8, Page 2017-2050, April 2025.
SUCNR1, activated by succinate, is a Gi‐ and Gq‐coupled receptor present at the plasma membrane and in endosomes. There are conflicting reports about the pro‐/anti‐inflammatory effects of the succinate‐SUCNR1 signaling axis, and these are likely due to localization‐dependent signaling.
Aenne‐Dorothea Liebing, Philipp Rabe, Petra Krumbholz, Christian Zieschang, Franziska Bischof, Angela Schulz, Susan Billig, Claudia Birkemeyer, Thanigaimalai Pillaiyar, Mikel Garcia‐Marcos, Robert Kraft, Claudia Stäubert   +11 more
wiley   +1 more source

Estrogen synthesized in the central nervous system enhances MC4R expression and reduces food intake

The FEBS Journal, EarlyView.
Estrogen is regulated by the rate‐limiting enzyme aromatase. This study examines how neuroestrogens, estrogen produced in the brain, regulate appetite through the hypothalamus. Using ovariectomized, aromatase knockout, and brain‐specific aromatase‐restored mice, the study found that neuroestrogens suppress appetite by influencing genes like Mc4r.
Takanori Hayashi, Kanako Kumamoto, Tatsuya Kobayashi, Xinfeng Hou, Shizuko Nagao, Nobuhiro Harada, Shinichiro Honda, Yohei Shimono, Eiji Nishio   +8 more
wiley   +1 more source

A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study

Headache: The Journal of Head and Face Pain, Volume 65, Issue 5, Page 779-790, May 2025.
Abstract Background The Trial of External trigeminal nerve stimulation (eTNS) for the Acute treatment of Migraine (TEAM) study demonstrated that eTNS use during active migraine resulted in significantly higher rates of resolution of migraine‐associated most bothersome symptom (MBS) compared to sham.
Gregory A. Panza, Michael A. L. Johnson, Deena E. Kuruvilla   +2 more
wiley   +1 more source

Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate the safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine (EM). Background Atogepant is an oral calcitonin gene‐related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine in adults and ...
Jessica Ailani, Richard B. Lipton, Andrew M. Blumenfeld, Laszlo Mechtler, Brad C. Klein, Molly Yizeng He, Jonathan H. Smith, Joel M. Trugman, Rosa de Abreu Ferreira, Elimor Brand‐Schieber   +9 more
wiley   +1 more source

Low serum 25‐hydroxyvitamin D levels in migraine are not related to headache frequency: A case‐control study in patients with high‐frequency/chronic migraine

Headache: The Journal of Head and Face Pain, Volume 65, Issue 5, Page 863-870, May 2025.
Abstract Background Serum 25‐hydroxyvitamin D (25[OH]D) concentrations have been shown to be low in patients with migraine, but results are controversial regarding the current role of vitamin D in migraine severity. Using a case–control design, we aimed to evaluate serum 25(OH)D levels in a group of females with high‐frequency episodic migraine/chronic
Marina Haro, Gabriel Gárate, José Luis Hernández, José Manuel Olmos, María Muñoz, Vicente González‐Quintanilla, Julio Pascual   +6 more
wiley   +1 more source

Central relaxin-3 administration causes hyperphagia in male Wistar rats. [PDF]

, 2005
B. M. C. McGowan, Bathgate, Bathgate, Bogatcheva, Burazin, Chen, Chen, E. L. Thompson, Fowler, Goto, Hsu, Hudson, Hudson, J. V. Gardiner, K. G. Murphy, K. L. Smith, Kamat, Kamegai, Kiwaki, Kong, Liu, Liu, M. A. Ghatei, M. M. Connolly, McKinley, N. E. White, S. A. Stanley, S. R. Bloom, Shintani, Sinnayah, Soloff, Stanley, Sudo, Thornton, Ward, Wren   +35 more
core   +1 more source

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To estimate the real‐world risk of cardiovascular events among patients with migraine treated with erenumab and other migraine preventive medications. Background Migraine preventive treatment with calcitonin gene‐related peptide (CGRP) pathway inhibitors, such as erenumab and others, may theoretically result in cardiovascular effects
David W. Dodick, Stewart J. Tepper, Jessica Ailani, Ani C. Khodavirdi, Nico Pannacciulli, Alan Fu, Shia T. Kent, Karminder Gill, Robert Urman, Sam S. Oh   +9 more
wiley   +1 more source

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to provide proof‐of‐concept that multi‐receptor antagonist peptides can be generated by covalently linking independent antagonist peptides that block calcitonin gene‐related peptide (CGRP8‐37) or pituitary adenylate cyclase‐activating peptide (PACAP)/vasoactive intestinal peptide (VIP) (PACAP6‐38) activity ...
Zoe Tasma, Andrew Siow, Paul W. R. Harris, Margaret A. Brimble, Debbie L. Hay, Christopher S. Walker   +5 more
wiley   +1 more source

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe.
Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola   +3 more
wiley   +1 more source